Sökning: onr:"swepub:oai:DiVA.org:uu-459712" >
Infantile myofibrom...
Infantile myofibromatosis : Excellent prognosis but also rare fatal progressive disease. Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry
-
Sparber-Sauer, Monika (författare)
-
Vokuhl, Christian (författare)
-
Seitz, Guido (författare)
-
visa fler...
-
Sorg, Benjamin (författare)
-
Tobias, Möllers (författare)
-
von Kalle, Thekla (författare)
-
Münter, Marc (författare)
-
Bielack, Stefan S (författare)
-
Ladenstein, Ruth (författare)
-
- Ljungman, Gustaf, 1958- (författare)
- Uppsala universitet,Institutionen för kvinnors och barns hälsa
-
Niggli, Felix (författare)
-
Frühwald, Michael (författare)
-
Loff, Stefan (författare)
-
Klingebiel, Thomas (författare)
-
Koscielniak, Ewa (författare)
-
visa färre...
-
(creator_code:org_t)
- 2021-10-11
- 2022
- Engelska.
-
Ingår i: Pediatric Blood & Cancer. - : John Wiley & Sons. - 1545-5009 .- 1545-5017. ; 69:3
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Infantile myofibromatosis (IM) is a rare benign soft tissue tumor and often a self-limiting disease but rarely includes life-threatening complications. Little is known about optimal treatment of primary localized (LD) and multifocal disease (MFD).Methods: Treatment and outcome of 95 children with IM registered within five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry (1981-2016) were evaluated.Results: LD was diagnosed in 71 patients at a median age of 0.4 years (range 0.0-17.7). MFD was present in 24 patients. The mainstay of treatment was watch-and-wait strategy (w&w) after initial biopsy or resection. Low-dose chemotherapy (CHT) was administered to 16/71 (23%) patients with LD and eight of 24 (33%) patients with MFD, imatinib was added in two. A delayed resection was possible in eight of 71 (11%) and five of 24 (21%) patients with LD and MFD, respectively. Overall, patients were alive in complete remission (n = 77) and partial remission (n = 10) at a median follow-up time of 3.4 years after diagnosis (range 0.01-19.4); no data available (n = 5). Three patients died of progressive disease (PD) despite CHT. Gender, tumor size, and location correlated with a favorable event-free survival (EFS) in patients with LD. The 5-year EFS and overall survival of patients with LD were 73% (±12, confidence interval [CI] 95%) and 95% (±6, CI 95%), respectively; for MFD 51% (±22, CI 95%) and 95% (±10, CI 95%).Cconclusion: Prognosis is excellent in patients with LD and MFD. Targeted treatment needs to be evaluated for rare fatal PD.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- CWS Group
- infantile myofibromatosis
- infants and children
- localized and multifocal disease
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sparber-Sauer, M ...
-
Vokuhl, Christia ...
-
Seitz, Guido
-
Sorg, Benjamin
-
Tobias, Möllers
-
von Kalle, Thekl ...
-
visa fler...
-
Münter, Marc
-
Bielack, Stefan ...
-
Ladenstein, Ruth
-
Ljungman, Gustaf ...
-
Niggli, Felix
-
Frühwald, Michae ...
-
Loff, Stefan
-
Klingebiel, Thom ...
-
Koscielniak, Ewa
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Pediatric Blood ...
- Av lärosätet
-
Uppsala universitet